EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:229233 - ritlecitinib
| Formula | C15H19N5O |
| Net Charge | 0 |
| Average Mass | 285.351 |
| Monoisotopic Mass | 285.15896 |
| SMILES | C=CC(=O)N1C[C@H](Nc2ncnc3nccc23)CC[C@@H]1C |
| InChI | InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1 |
| InChIKey | CBRJPFGIXUFMTM-WDEREUQCSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Chemical Role: | Bronsted base A molecular entity capable of accepting a hydron from a donor (Brønsted acid). |
| Biological Roles: | EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that specifically blocks the action of non-specific protein-tyrosine kinase (EC 2.7.10.2). immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. |
| Applications: | dermatologic drug A drug used to treat or prevent skin disorders or for the routine care of skin. anti-inflammatory drug A substance that reduces or suppresses inflammation. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. antirheumatic drug A drug used to treat rheumatoid arthritis. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| ritlecitinib (CHEBI:229233) has role anti-inflammatory drug (CHEBI:35472) |
| ritlecitinib (CHEBI:229233) has role antirheumatic drug (CHEBI:35842) |
| ritlecitinib (CHEBI:229233) has role dermatologic drug (CHEBI:50177) |
| ritlecitinib (CHEBI:229233) has role EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor (CHEBI:76617) |
| ritlecitinib (CHEBI:229233) has role immunosuppressive agent (CHEBI:35705) |
| ritlecitinib (CHEBI:229233) is a N-acylpiperidine (CHEBI:48591) |
| ritlecitinib (CHEBI:229233) is a acrylamides (CHEBI:22216) |
| ritlecitinib (CHEBI:229233) is a pyrrolopyrimidine (CHEBI:38670) |
| ritlecitinib (CHEBI:229233) is a secondary amino compound (CHEBI:50995) |
| ritlecitinib (CHEBI:229233) is a tertiary carboxamide (CHEBI:140326) |
| ritlecitinib (CHEBI:229233) is conjugate base of ritlecitinib(1+) (CHEBI:229235) |
| Incoming Relation(s) |
| ritlecitinib(1+) (CHEBI:229235) is conjugate acid of ritlecitinib (CHEBI:229233) |
| IUPAC Name |
|---|
| 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one |
| INNs | Source |
|---|---|
| ritlecitinib | WHO MedNet |
| ritlecitinib | WHO MedNet |
| ritlécitinib | WHO MedNet |
| ritlecitinibum | WHO MedNet |
| Synonyms | Source |
|---|---|
| PF-06651600 | DrugBank |
| PF 06651600 | ChEBI |
| PF06651600 | ChEBI |
| Manual Xrefs | Databases |
|---|---|
| DB14924 | DrugBank |
| Ritlecitinib | Wikipedia |
| Registry Numbers | Sources |
|---|---|
| CAS:1792180-81-4 | DrugBank |
| Citations |
|---|